Citigroup starts Arrowhead Pharmaceuticals with a $108 price target
Citigroup initiated coverage on Arrowhead Pharmaceuticals with a buy rating and announced a $108.00/share price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.